Mydecine Innovations today announced it entered a definitive share exchange agreement to acquire 100% of NeuroPharm.
Mydecine Innovations will acquire all issued and outstanding shares in the capital of NeuroPharm for $6 million, which will be payable in common shares in the capital of the company.
NeuroPharm is currently developing evidence-based medicine of psychedelic based therapies to address mental health conditions that are frequently experienced by veterans and frontline workers.
Get the full story on our sister site, Drug Discovery & Development.